Clinical trials: Moderate-to-severe Psoriasis
Psoriasis
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT03895372
- Testing
- PF-06826647
- Where
- 45 sites in United States, Canada and 2 more
- Volunteers
- 179 people
- Sponsor
- Pfizer
Psoriasis
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis
The purpose of this study is to assess the safety, tolerability, immunogenicity, and clinical effects of AMG 811 following single subcutaneous dose administration in subjects with moderate to severe psoriasis.
- Trial name
- NCT01510951
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 9 people
- Sponsor
- Amgen
Psoriasis, Vascular Inflammation
Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis
This study is to determine the effect of adalimumab on inflammation of blood vessels that could lead to heart attack in patients with psoriasis.
- Conditions
- Psoriasis, Vascular Inflammation, Coronary Atherosclerosis
- Trial name
- NCT00940862
- Testing
- adalimumab, UVB Phototherapy, Topical treatment
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Transitioning From Cyclosporine to Alefacept in Psoriasis
The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.
- Trial name
- NCT00143806
- Testing
- Transitioning patients from cyclosporine to alefacept
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Psoriasis, Plaque-type Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
- Trial name
- NCT00773734
- Testing
- Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg
- Where
- 35 sites in United States, Canada
- Volunteers
- 352 people
- Sponsor
- Amgen
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
- Trial name
- BE CARING (NCT06888193)
- Testing
- Bimekizumab
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 20 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Chronic Plaque Psoriasis, Psoriasis
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
- Trial name
- NCT02581345
- Testing
- M923, Humira
- Where
- 90 sites in United States, Bulgaria and 7 more
- Volunteers
- 572 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Psoriasis
Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .
- Trial name
- NCT02933528
- Testing
- DSXS Topical product
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.
- Trial name
- OASIS-1 (NCT03482011)
- Testing
- Mirikizumab
- Where
- 69 sites in United States, Germany and 7 more
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects
Assess the efficacy and safety of alefacept with nbUVB compared to alefacept alone in chronic plaque psoriasis subjects. Combination therapy may improve the clinical response to psoriatic subjects as both modalities have an…
- Trial name
- NCT00658606
- Testing
- alefacept, Narrow Band UVB Phototherapy
- Where
- 12 sites in Canada
- Volunteers
- 98 people
- Sponsor
- Astellas Pharma Inc
Plaque Psoriasis
Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
This study is a multicenter, randomized, double-blind, parallel-arm, Phase 3 study designed to compare efficacy, safety, immunogenicity, and PK of BAT2306 with Cosentyx in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT05377944
- Testing
- BAT2306, EU-approved Cosentyx
- Where
- China
- Volunteers
- 502 people
- Sponsor
- Bio-Thera Solutions
Moderate to Severe Plaque Psoriasis
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
This is a first-in-human, phase 1, single-center, randomized, double blinded, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, of 608 following subcutaneous injection in healthy subjects.
- Trial name
- NCT04367441
- Testing
- 608
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque…
- Trial name
- NCT03988439
- Testing
- IDP-118 Lotion
- Where
- 9 sites in United States, Dominican Republic and 1 more
- Volunteers
- 16 people
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque…
- Trial name
- EVERLAST-A (NCT07090330)
- Testing
- ORKA-001 Induction Dose, ORKA-001 Maintenance Dose
- Where
- 26 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Oruka Therapeutics, Inc.
Plaque Psoriasis
A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis
The purpose of this research study is to assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GLPG3667 in multiple daily oral doses in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT04594928
- Testing
- GLPG3667
- Where
- 7 sites in Bulgaria, Poland and 1 more
- Volunteers
- 30 people
- Sponsor
- Lakefront Biotherapeutics NV
Vascular Inflammation, Psoriasis
Cytokines and Vascular Inflammation in Psoriasis
Psoriasis is an inflammatory disease involving the skin, the joints and the vascular compartment. The mechanisms linking inflammation in the skin and joints and in the vascular walls are poorly understood.
- Conditions
- Vascular Inflammation, Psoriasis, Coronary Atherosclerosis
- Trial name
- NCT02305953
- Where
- 4 sites in Canada
- Volunteers
- 96 people
- Sponsor
- Innovaderm Research Inc.
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis (Ps) Registry
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
- Trial name
- NCT00799877
- Where
- 339 sites in United States, Austria and 12 more
- Volunteers
- 6,065 people
- Sponsor
- AbbVie
Psoriasis
Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis
Vitamins modulating homocysteine affect both TNF-alpha, vascular endothelial growth factor, and theoretically enhance the anti-inflammatory version of NOS thus hopefully increasing the efficacy and reducing the chance of some…
- Trial name
- NCT01704599
- Testing
- Humira Then Humira plus 3 B vitamins
- Volunteers
- 8 people
- Sponsor
- Wayne State University